Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Gilead Sciences (NQ: GILD )

79.97 +0.97 (+1.23%)
Streaming Delayed Price Updated: 12:09 PM EDT, Sep 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Dogecoin Fulfills 'Doge Day' Goal Of 69 Cents Weeks Later, Surpasses Snapchat, GM In Valuation
The joke cryptocurrency Dogecoin (DOGE) touched a fresh all-time high in the early hours of Wednesday, crossing the much sought-af... 
Via Benzinga
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir. 
Via The Motley Fool
2 Must-Own Biotech Stocks To Buy In May
After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks such as Gilead Sciences... 
Via Talk Markets
9 Health Care Stocks Showing Unusual Options Activity In Today's Session
Here's the list of some unusual options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest... 
Via Benzinga
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap... 
Via Talk Markets
Exposures COVID-19
Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings
Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but... 
Via Benzinga
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Gilead's Q1 Results Show Just How Much the Biotech Is Relying on Its COVID Drug
With Veklury, Gilead delivered solid revenue growth in Q1. Without the COVID drug, it was an entirely different story. 
Via The Motley Fool
Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript
GILD earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
15 Stocks Moving In Thursday's After-Hours Session
Gainers Amazon (NASDAQ: AMZN) shares are trading higher after the company reported better-than-expected Q1 EPS and sales results. The company also issued Q2 sales guidance above... 
Via Benzinga
Recap: Gilead Sciences Q1 Earnings
Shares of Gilead Sciences (NASDAQ:GILD) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 23.81% year over... 
Via Benzinga
Gilead Stock Dives On Wide First-Quarter Sales Miss, Earnings Meet
Late Thursday, Gilead reported adjusted income of $2.08 a share on $6.42 billion in sales for its first quarter. In response, Gilead stock fell. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Healthcare ETFs on Radar As Q1 Earnings Unfold
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production
Merck & Co Inc (NYSE: MRK) has partnered with five Indian generic drugmakers to expand production and access to Molnupiravir, its experimental oral... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
The Smartest Stocks to Buy With $1,000 Right Now
These fundamentally strong stocks can yield solid returns in the coming years. 
Via The Motley Fool
Topics Electric Vehicles
Exposures Electric Vehicles
Should You Buy Gilead Sciences in April?
Gilead Sciences had a stellar 2020, but this year is looking a little more perilous. 
Via The Motley Fool
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
7 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
Why Tonix Pharmaceuticals Stock Is Jumping Today
The company struck a deal to bolster its COVID-19 pipeline. 
Via The Motley Fool
Exposures COVID-19
Humanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study
Humanigen Inc (NASDAQ: HGEN) has announced data from the Phase 1b portion of the ZUMA-19 trial evaluating its lead candidate lenzilumab in patients... 
Via Benzinga
What Does Gilead Sciences Debt Look Like?
Shares of Gilead Sciences (NASDAQ:GILD) fell by 0.30% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences... 
Via Benzinga
SPACs Attack Recap: 5 Deals, Rumors And Headline News
It was another busy week for the SPAC market with numerous deal announcements and rumored deals. Benzinga's "SPACs Attack" covered it all throughout the week. Here... 
Via Benzinga
Could Vir Biotechnology Be a Millionaire Maker Stock?
Vir is developing treatments in billion-dollar markets. 
Via The Motley Fool
Exposures COVID-19
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Cancer Biotech Tango Therapeutics Picks Boxer Capital's SPAC To Go Public Via $353M Merger
The latest biotech-SPAC deal has arrived with Cambridge, Massachusetts-based Tango Therapeutics announcing its reverse merger with Boxer Capital’s ... 
Via Benzinga
Drugmakers Are Vying for a Multibillion-Dollar Market
Too bad there are issues with side effects. 
Via The Motley Fool
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.